Spironolactone improves lung diffussion in chronic heart failure

Research output: Contribution to journalArticlepeer-review


Aims: To evaluate whether anti-aldosteronic treatment influences lung diffusion (DLco) in chronic heart failure (HF) patients. Spironolactone improves clinical conditions and prognosis in chronic HF and reduces connective tissue matrix turnover; DLco abnormalities in chronic HF are related to increase in fibrosis and connective tissue derangement. Methods and results: Thirty stable chronic HF patients, with reduced DLco (2 16.8 ± 1.9 vs. 18.6 ± 2.2 mL/min/kg). Increments of DLco and peak VO2 were linearly related (R = 0.849, P <0.001). Conclusion: These data show a positive effect of spironolactone on gas diffusion and exercise capacity suggesting a novel mechanism by which anti-aldosteronic drugs improve HF clinical condition and prognosis.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalEuropean Heart Journal
Issue number2
Publication statusPublished - Jan 2005


  • Anti-aldosteronic drugs
  • Exercise
  • Heart failure
  • Lung diffusion capacity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Spironolactone improves lung diffussion in chronic heart failure'. Together they form a unique fingerprint.

Cite this